Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

Phase 1

Active, not recruiting

Conditions: Renal Pelvis Neoplasms
Carcinoma, Transitional Cell
Urinary Bladder Neoplasms
Urologic Neoplasms
Urothelial Cancer
Ureteral Neoplasms
Urethral Neoplasms

Interventions: Drug: enfortumab vedotin (EV)
Drug: pembrolizumab
Drug: cisplatin
Drug: carboplatin
Drug: gemcitabine

First Posted Date: 2017-09-20

Last Posted Date: 2024-12-27

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 348

Registration Number: NCT03288545

Locations: 🇺🇸
Piedmont Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Winship Cancer Institute / Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

and more 103 locations

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Phase 1

Active, not recruiting

Conditions: Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

Interventions: Drug: 5-Fluorouracil (5-FU)
Drug: BL-8040
Biological: PEGylated recombinant human hyaluronidase (PEGPH20)
Biological: Ramucirumab
Drug: Linagliptin
Drug: Leucovorin
Drug: Cobimetinib
Drug: Paclitaxel
Drug: Cisplatin
Drug: Oxaliplatin
Drug: Tiragolumab
Drug: Atezolizumab

First Posted Date: 2017-09-13

Last Posted Date: 2024-10-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 410

Registration Number: NCT03281369

Locations: 🇺🇸
Uni of Southern California; Norris Comprehensive Cancer Ctr, Los Angeles, California, United States
🇺🇸
Tennessee Oncology - Nashville, Nashville, Tennessee, United States
🇦🇺
Peter MacCallum Cancer Centre; Medical Oncology, Melbourne, Victoria, Australia

and more 33 locations

Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas

Phase 1

Completed

Conditions: Soft Tissue Sarcoma
Bone Sarcoma

Interventions: Drug: Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent]
Drug: Nivolumab 100 MG/10 ML [Opdivo]
Drug: Epirubicin
Drug: Ifosfamide
Drug: Doxorubicin
Drug: Dacarbazine
Drug: Cisplatin
Drug: Methotrexate

First Posted Date: 2017-09-11

Last Posted Date: 2024-08-13

Lead Sponsor: Grupo Espanol de Investigacion en Sarcomas

Target Recruit Count: 197

Registration Number: NCT03277924

Locations: 🇮🇹
Istituto Nazionale dei Tumori, Milano, Italy
🇪🇸
Hospital Universitario Virgen del Rocío, Sevilla, Spain
🇪🇸
Hospital Universitari i Politècnic La Fe, Valencia, Spain

and more 10 locations

Cisplatin in Castration Resistant Prostate Cancer

Early Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Cisplatin

First Posted Date: 2017-09-08

Last Posted Date: 2024-06-10

Lead Sponsor: University of Rochester

Target Recruit Count: 12

Registration Number: NCT03275857

Locations: 🇺🇸
Wilmot Cancer Institute, Rochester, New York, United States

A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages

Phase 2

Completed

Conditions: Paranasal Sinus Cancer
Nasal Cavity Tumor
Nasal Cavity Adenocarcinoma

Interventions: Drug: Cisplatin
Radiation: Adjuvant Proton Radiotherapy
Procedure: Endoscopic Resection
Drug: cisplatin and etoposide

First Posted Date: 2017-09-07

Last Posted Date: 2023-10-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 3

Registration Number: NCT03274414

Locations: 🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸
Memoral Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States

and more 2 locations

Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection

Phase 3

Conditions: NSCLC

Interventions: Drug: Jinfukang Koufuye
Drug: Docetaxel
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2017-08-31

Last Posted Date: 2017-09-14

Lead Sponsor: lihegen

Target Recruit Count: 144

Registration Number: NCT03269162

Emulsion Versus Suspension in Chemoembolization for Hepatocellular Carcinoma

Not Applicable

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Cisplatin

First Posted Date: 2017-08-31

Last Posted Date: 2024-11-15

Lead Sponsor: Chinese University of Hong Kong

Target Recruit Count: 80

Registration Number: NCT03268499

Locations: 🇭🇰
Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong

A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors

Phase 1

Completed

Conditions: Pancreatic Ductal Adenocarcinoma
Colorectal Cancer
Non Small Cell Lung Cancer
Triple Negative Breast Cancer

Interventions: Biological: CAN04
Drug: Gemcitabine
Drug: Cisplatin
Drug: Carboplatin
Drug: Nab-paclitaxel
Drug: Pemetrexed

First Posted Date: 2017-08-30

Last Posted Date: 2024-08-22

Lead Sponsor: Cantargia AB

Target Recruit Count: 167

Registration Number: NCT03267316

Locations: 🇩🇰
Rigshospitalet, Department of Oncology, Copenhagen, Denmark
🇦🇹
Medizinische Universität Wien, Vienna, Austria
🇦🇹
Landeskrankenhaus Salzburg, Salzburg, Austria

and more 22 locations

Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)

Phase 2

Completed

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Nivolumab
Drug: Cisplatin
Radiation: Radiation Therapy

First Posted Date: 2017-08-30

Last Posted Date: 2025-01-06

Lead Sponsor: Sue Yom

Target Recruit Count: 40

Registration Number: NCT03267498

Locations: 🇸🇬
National University Hospital Singapore, Singapore, Singapore
🇺🇸
University of California, San Francisco, San Francisco, California, United States

Pembrolizumab in Biliary Tract Cancer

Phase 2

Completed

Conditions: Biliary Tract Cancer
Metastatic Cancer
Advanced Cancer
Gallbladder Cancer

Interventions: Drug: Pembrolizumab
Drug: Cisplatin
Drug: Gemcitabine

First Posted Date: 2017-08-24

Last Posted Date: 2023-11-03

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 50

Registration Number: NCT03260712

Locations: 🇬🇧
Nottingham University Hospitals NHS Trust - City Hospital, Nottingham, United Kingdom
🇪🇸
Hospital Universitario 12 De Octubre, Madrid, Spain
🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom

and more 4 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy